Literature DB >> 19349713

Epstein-Barr virus WZhet DNA can induce lytic replication in epithelial cells in vitro, although WZhet is not detectable in many human tissues in vivo.

Julie L Ryan1, Richard J Jones, Sandra H Elmore, Shannon C Kenney, George Miller, Jane C Schroeder, Margaret L Gulley.   

Abstract

OBJECTIVE: WZhet is a rearranged and partially deleted form of the Epstein-Barr virus (EBV) genome in which the BamH1W region becomes juxtaposed with and activates BZLF1, resulting in constitutive viral replication. We tested whether WZhet induces viral replication in epithelial cells, and we studied its prevalence in a wide range of lesional tissues arising in vivo.
METHODS: A quantitative real-time PCR assay targeting EBV WZhet DNA was developed to measure this recombinant form of the EBV genome.
RESULTS: WZhet DNA was undetectable in any of 324 plasma or paraffin-embedded tissue samples from patients with EBV-associated and EBV-negative disorders. These included specimens from patients with Hodgkin or non-Hodgkin lymphoma, post-transplant lymphoproliferation, nasopharyngeal or gastric adenocarcinoma, and infectious mononucleosis. However, WZhet DNA was detected in vitro in EBV-infected AGS gastric cancer cells. Additionally, transient transfection of infected AGS gastric cancer cells showed that viral replication could be induced by a WZhet plasmid.
CONCLUSION: This is the first evidence that WZhet induces the EBV lytic cycle in an epithelial cell line. Our negative findings in natural settings suggest that WZhet is a defective viral product that thrives in the absence of a host immune system but is rarely present in vivo. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19349713      PMCID: PMC2865398          DOI: 10.1159/000210833

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  34 in total

1.  Sequences of the Epstein-Barr Virus (EBV) large internal repeat form the center of a 16-kilobase-pair palindrome of EBV (P3HR-1) heterogeneous DNA.

Authors:  H B Jenson; P J Farrell; G Miller
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

2.  Spontaneous loss of viral episomes accompanying Epstein-Barr virus reactivation in a Burkitt's lymphoma cell line.

Authors:  S K Srinivas; J T Sample; J W Sixbey
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

3.  An enzyme-linked immunosorbent assay for the measurement of human IgA antibody responses to Epstein-Barr virus membrane antigen.

Authors:  P J Durda; M Sullivan; E Kieff; G R Pearson; H Rabin
Journal:  Intervirology       Date:  1993       Impact factor: 1.763

4.  A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma.

Authors:  T T Yip; R K Ngan; W H Lau; Y F Poon; I Joab; C Cochet; A K Cheng
Journal:  Cancer       Date:  1994-11-01       Impact factor: 6.860

5.  Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.

Authors:  T Hadar; M Rahima; E Kahan; J Sidi; E Rakowsky; B Sarov; I Sarov
Journal:  J Med Virol       Date:  1986-12       Impact factor: 2.327

6.  Strain variation in Epstein-Barr virus immediate early genes.

Authors:  G Packham; M Brimmell; D Cook; A J Sinclair; P J Farrell
Journal:  Virology       Date:  1993-02       Impact factor: 3.616

7.  Thymic carcinoma with a defective Epstein-Barr virus encoding the BZLF1 trans-activator.

Authors:  D F Patton; R C Ribeiro; J J Jenkins; J W Sixbey
Journal:  J Infect Dis       Date:  1994-07       Impact factor: 5.226

8.  Epstein-Barr virus and Hodgkin's disease: a comparative immunological, in situ hybridization, and polymerase chain reaction study.

Authors:  A F Lauritzen; U Hørding; H W Nielsen
Journal:  APMIS       Date:  1994-07       Impact factor: 3.205

9.  The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases.

Authors:  J Xu; A Ahmad; M Blagdon; M D'Addario; J F Jones; R Dolcetti; E Vaccher; U Prasad; J Menezes
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

10.  Human oropharyngeal lesions with a defective Epstein-Barr virus that disrupts viral latency.

Authors:  Y J Gan; P Shirley; Y Zeng; J W Sixbey
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

View more
  2 in total

1.  Colon composited B cell lymphoma involving intestinal mesenteric lymph nodes combined with adenocarcinoma and schistosome infection: a case report.

Authors:  Hanzhen Xiong; Juan Chen; Shaoyan Liu; Hui Chen; Qingping Jiang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 2.  Epstein-barr virus sequence variation-biology and disease.

Authors:  Stelios Tzellos; Paul J Farrell
Journal:  Pathogens       Date:  2012-11-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.